-
公开(公告)号：US20100330110A1
公开(公告)日：2010-12-30
申请号：US12871765
申请日：2010-08-30
申请人： William H. Robinson , David L. Hirschberg , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz , Hideki Garren
发明人： William H. Robinson , David L. Hirschberg , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz , Hideki Garren
CPC分类号： A61K39/0008 , G01N33/564 , G01N33/6854 , G01N2800/102 , G01N2800/24 , G01N2800/52
摘要： This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.
摘要翻译： 本发明提供了确定个体中抗体特异性谱的方法。 该特异性特征揭示了个体对多种抗原和/或自身抗原，变应原，移植抗原等表位的免疫应答。通过将包含抗体的患者样品与阵列的结合来确定抗体特异性谱。 阵列可以包括抗原和表位。 本发明还提供了用于确定抗原或表位特异性谱的方法和方法，所述抗原或表位特异性特征可用于开发针对免疫相关疾病的通用和个体化诊断和治疗，包括自身免疫疾病，变态反应和移植排斥反应。
-
公开(公告)号：US07785819B2
公开(公告)日：2010-08-31
申请号：US10120578
申请日：2002-04-10
申请人： William H. Robinson , David L. Hirschberg , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz , Hideki Garren
发明人： William H. Robinson , David L. Hirschberg , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz , Hideki Garren
IPC分类号： G01N33/00
CPC分类号： A61K39/0008 , G01N33/564 , G01N33/6854 , G01N2800/102 , G01N2800/24 , G01N2800/52
摘要： This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.
摘要翻译： 本发明提供了确定个体中抗体特异性谱的方法。 该特异性特征揭示了个体对多种抗原和/或自身抗原，变应原，移植抗原等表位的免疫应答。通过将包含抗体的患者样品与阵列的结合来确定抗体特异性谱。 阵列可以包括抗原和表位。 本发明还提供了用于确定抗原或表位特异性谱的方法和方法，所述抗原或表位特异性特征可用于开发针对免疫相关疾病的通用和个体化诊断和治疗，包括自身免疫疾病，变态反应和移植排斥反应。
-
公开(公告)号：US20090281170A1
公开(公告)日：2009-11-12
申请号：US12467857
申请日：2009-05-18
申请人： Paulo Fontoura , Hideki Garren , William H. Robinson , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz
发明人： Paulo Fontoura , Hideki Garren , William H. Robinson , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz
IPC分类号： A61K31/711
CPC分类号： A61K39/001 , A61K38/2026 , A61K39/0007 , A61K39/0008 , A61K48/00 , A61K2039/53 , A61K2039/55522 , A61K2039/55561 , C07K2319/30
摘要： This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal.
-
公开(公告)号：US07544669B2
公开(公告)日：2009-06-09
申请号：US10302098
申请日：2002-11-21
申请人： Paulo Fontoura , Hideki Garren , William H. Robinson , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz
发明人： Paulo Fontoura , Hideki Garren , William H. Robinson , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz
CPC分类号： A61K39/001 , A61K38/2026 , A61K39/0007 , A61K39/0008 , A61K48/00 , A61K2039/53 , A61K2039/55522 , A61K2039/55561 , C07K2319/30
摘要： This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal.
摘要翻译： 本发明提供了一种治疗或预防与一种或多种自身蛋白，多肽或肽存在或参与非生理过程的一种或多种自身相关的动物疾病的方法， 所述动物包括向所述动物施用包含编码与所述疾病相关的自身蛋白质多肽或多肽的多核苷酸的自身载体。 施用包含编码自身蛋白，多肽或多肽的多核苷酸的自身载体调节对自身蛋白质的多肽或肽的免疫应答 （s）表示自我向量的管理。 本发明还提供了一种组合物，其包含编码一种或多种自身蛋白质，多肽或多肽或多肽的多核苷酸，所述多肽或多肽在治疗动物中非生理性地存在，可用于治疗或预防相关疾病 其中存在于动物的非生理过程的和/或靶中的自身蛋白质，多肽或多肽。
-
公开(公告)号：US20090264515A1
公开(公告)日：2009-10-22
申请号：US12467866
申请日：2009-05-18
申请人： Paulo Fontoura , Hideki Garren , William H. Robinson , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz
发明人： Paulo Fontoura , Hideki Garren , William H. Robinson , Lawrence Steinman , Pedro Jose Ruiz , Paul J. Utz
IPC分类号： A61K31/7088 , A61P21/00
CPC分类号： A61K39/001 , A61K38/2026 , A61K39/0007 , A61K39/0008 , A61K48/00 , A61K2039/53 , A61K2039/55522 , A61K2039/55561 , C07K2319/30
摘要： This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal.
摘要翻译： 本发明提供了一种治疗或预防与一种或多种自身蛋白，多肽或肽存在或参与非生理过程的一种或多种自身相关的动物疾病的方法， 所述动物包括向所述动物施用包含编码与所述疾病相关的自身蛋白质多肽或多肽的多核苷酸的自身载体。 施用包含编码自身蛋白，多肽或多肽的多核苷酸的自身载体调节对自身蛋白质的多肽或肽的免疫应答 （s）表示自我向量的管理。 本发明还提供了一种组合物，其包含编码一种或多种自身蛋白质，多肽或多肽或多肽的多核苷酸，所述多肽或多肽在治疗动物中非生理性地存在，可用于治疗或预防相关疾病 其中存在于动物的非生理过程的和/或靶中的自身蛋白质，多肽或多肽。
-
公开(公告)号：US08835391B2
公开(公告)日：2014-09-16
申请号：US12931001
申请日：2011-01-21
IPC分类号： A61K38/00 , A61K38/17 , A61K31/711
CPC分类号： A61K31/711 , A61K38/1709
摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。
-
公开(公告)号：US20110318346A1
公开(公告)日：2011-12-29
申请号：US13135079
申请日：2011-06-23
IPC分类号： A61K39/395 , A61K31/7088 , A61P9/10 , A61P19/02 , A61P25/16 , A61P25/28 , A61P9/00 , A61K38/17 , A61P25/00
CPC分类号： A61K38/1709 , A61K31/711 , A61K39/395 , A61K45/06 , A61K47/48415 , A61K47/6811 , A61K2039/505 , C07K16/18 , C07K2317/52 , C07K2317/75
摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。
-
公开(公告)号：US07875589B2
公开(公告)日：2011-01-25
申请号：US12001553
申请日：2007-12-11
IPC分类号： A61K38/16
CPC分类号： A61K31/711 , A61K38/1709
摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。
-
公开(公告)号：US08771689B2
公开(公告)日：2014-07-08
申请号：US13135079
申请日：2011-06-23
IPC分类号： A61K39/395 , A61K38/00
CPC分类号： A61K38/1709 , A61K31/711 , A61K39/395 , A61K45/06 , A61K47/48415 , A61K47/6811 , A61K2039/505 , C07K16/18 , C07K2317/52 , C07K2317/75
摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。
-
公开(公告)号：US20110160142A1
公开(公告)日：2011-06-30
申请号：US12931001
申请日：2011-01-21
CPC分类号： A61K31/711 , A61K38/1709
摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.034 秒)